Catalyst Brief

← Calendar

Readoutin 45d

Xenon Pharmaceuticals Inc. — Azetukalner

Phase 3 primary completion: An Open-Label Study of Azetukalner in Major Depressive Disorder.

Date
Jan 2027
Type
Readout
Indication
Major Depressive Disorder

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.